Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2021 Oct 24;174:102357. doi: 10.1016/j.plefa.2021.102357

Figure 2a-. Simplified model depicting relationships and structures of endogenous lipid mediators, stable analogs, and small molecules containing proposed pharmacophores.

Figure 2a-

(A) Membranes are enriched in 13-hydroxy-9,10-epoxy-octadecenoate and 13,9,10-trihydroxy-octadecenoate; (B) These compounds are released as free acids via lipasemediated hydrolysis; (C) 13-hydroxy-9,10-epoxy-octadecenoate is converted to 13,9,10-trihydroxy-octadecenoate in low pH environment or by epoxide hydrolase; (D) Free 13-hydroxy-9,10-epoxy-octadecenoate (D1) and 13,9,10-trihydroxy-octadecenoate (D2) are inactivated by re-esterification; (E) Free 13-hydroxy-9,10-epoxy-octadecenoate and 13,9,10-trihydroxy-octadecenoate are dehydrogenated to produce 13-keto-9,10-epoxy-octadecenoate (E1) and 13-keto-9,10-dihydroxy-octadecenoate (E2).